GlaxoSmithKline (GSK) has completed the partial sale of Aspen Pharmacare, the drug company announced on Wednesday.The group has disposed 28.2m ordinary shares in Aspen at a price of 250 South African Rand (ZAR) per share, raising gross proceeds of 7,059m ZAR.The sale will leave GSK with 56.5m ordinary shares in Aspen or 12.4% of issued share capital. GSK said it will retain a seat on Aspen's board and intends to remain a significant shareholder of Aspen. The firm will not sell of any further shares in Aspen for a period of six months following completion, subject to certain limited exceptions."Net proceeds of the transaction will be approximately £425m at the prevailing exchange rate on November 19th. Proceeds will be used for "general corporate purposes", GSK said. RD